FDA plans to phase out animal testing requirements Press Coverage FDA plans to phase out animal testing requirements Discover how the FDA plans to replace animal testing with AI and organ-on-chip technologies for…CertaraApril 10, 2025
Postmarketing Assessment of Antibody–Drug Conjugates: Proof-of-Concept Using Model-Based Meta-Analysis and a Clinical Utility Index Approach Publication Postmarketing Assessment of Antibody–Drug Conjugates: Proof-of-Concept Using Model-Based Meta-Analysis and a Clinical Utility Index Approach This study explores a model-based meta-analysis (MBMA) and a clinical utility index (CUI) approach to…CertaraMarch 4, 2025
2025 cell and gene challenges: Scalability, supply chain and manufacturing Press Coverage 2025 cell and gene challenges: Scalability, supply chain and manufacturing Explore insights on 2025 challenges in cell and gene therapy, including commercial viability, with expert…CertaraFebruary 3, 2025
AI in Life Sciences Finds an Early Success and Will Continue in 2025 Press Coverage AI in Life Sciences Finds an Early Success and Will Continue in 2025 Fran Brown highlights how AI in life sciences drives more precise drug development and reduces…CertaraDecember 24, 2024
CMS Cell and Gene Therapy (CGT) Access Model Explained: The Most Significant Drug Pricing Legislation You’ve Never Heard Of Blog CMS Cell and Gene Therapy (CGT) Access Model Explained: The Most Significant Drug Pricing Legislation You’ve Never Heard Of December 13, 2024 The Centers for Medicare & Medicaid Services (CMS) is piloting a program…CertaraDecember 13, 2024
Advancing pharmacometrics in Africa – Transition from capacity development toward job creation Publication Advancing pharmacometrics in Africa – Transition from capacity development toward job creation This CPT article showcases, the Applied Pharmacometrics Training (APT) program, launched in 2021 by Pharmacometrics…CertaraDecember 9, 2024
A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population Publication A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population CertaraNovember 7, 2024
Semi-mechanistic Model of ATG-101, a PD-L1/4-1BB Bispecific Antibody, for Treatment of Solid Tumors Poster Semi-mechanistic Model of ATG-101, a PD-L1/4-1BB Bispecific Antibody, for Treatment of Solid Tumors Abstract Trimer formation is key to the pharmacology of the bispecific ATG-101 but is difficult…CertaraSeptember 16, 2024
Blinatumomab Trimer Formation Poster Blinatumomab Trimer Formation Insights from a Mechanistic PKPD Model on the Implications for Switching from Infusion to Subcutaneous…CertaraSeptember 16, 2024
Dose Selection for DuoBody®-PD-L1x4-1BB (GEN1046) Poster Dose Selection for DuoBody®-PD-L1x4-1BB (GEN1046) Abstract DuoBody®-PD-L1x4-1BB (GEN1046) is an investigational, first-in-class, bispecific antibody designed to elicit an antitumor immune…CertaraSeptember 9, 2024